NovoCure (NVCR) Total Current Liabilities (2014 - 2026)

NovoCure has disclosed Total Current Liabilities across 13 years of filings, most recently posting $217.6 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $217.6 million, down 70.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $217.6 million (down 70.73% YoY), and the FY2025 annual result was $223.2 million, down 70.49% from the prior year.
• Total Current Liabilities came in at $217.6 million for Q1 2026 at NovoCure, down from $223.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $776.0 million in Q3 2025 to a low of $127.8 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $169.2 million (2024), against an average of $337.0 million.
• Across the five-year window, Total Current Liabilities soared 367.67% in 2024 and plunged 70.73% in 2026, its largest moves.
• NovoCure's Total Current Liabilities stood at $158.8 million in 2022, then gained by 12.81% to $179.1 million in 2023, then jumped by 322.3% to $756.4 million in 2024, then tumbled by 70.49% to $223.2 million in 2025, then dropped by 2.53% to $217.6 million in 2026.
• The last three Total Current Liabilities figures came in at $217.6 million (Q1 2026), $223.2 million (Q4 2025), and $776.0 million (Q3 2025), per Business Quant data.